Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03604029
Other study ID # W81XWH17C0029
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 7, 2019
Est. completion date February 28, 2022

Study information

Verified date September 2020
Source Nonin Medical, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a study intended to validate a new set of guidelines for a device that uses light to measure the amount of oxygen in the muscles of injured and non-injured legs and forearms in specific situations.


Description:

This is a study intended to validate a new set of guidelines for a device that uses light to measure the amount of oxygen in the muscles of injured and non-injured legs and forearms in specific situations. The name of this technology is NIRS (near-infrared spectroscopy). We have shown NIRS can be helpful in diagnosing ACS. We think two of the primary advantages of this device are that it is noninvasive (not painful) and it collects data continuously, so that if the disease develops, it can be detected early and treated appropriately. We have studied the capabilities of NIRS for many years. The last step in the process of proving NIRS and its use in ACS will be to test our recommendations and guidelines. The goal of this study is to test and prove our clinical guidelines we developed through previous work. This is an interventional study, which means the data we collect will be used to manage the patient and their care.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 300
Est. completion date February 28, 2022
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Aged 18 to 65 years

2. Ability to be enrolled within 12 hours of qualifying injury

3. Must have at least one uninjured upper or lower extremity

4. Must have a "severe leg injury" meeting one of the following anatomical locations and mechanisms of injury.

Anatomic Location:

1. Tibia/fibula shaft fracture

2. Tibial plateau fracture (including lateral split depression, lateral depression, medial plateau, bicondylar, and bicondylar with metaphyseal extension)

3. Gunshot wound to leg without tibia fracture

High Energy Mechanism of Injury (MOI):

1. Fall from more than 5-foot height

2. Motor vehicle collision (more than 15mph)

3. Motor vehicle versus pedestrian accident

4. High velocity gunshot wound (with or without tibia fracture)

5. Crush injury

6. Sport/recreation

Exclusion Criteria:

1. Application of NIRS monitoring would be an impediment to care

2. Known prior injury, surgery, or disease of the lower extremity (including thigh) that alters normal circulation in the leg (including peripheral vascular disease)

3. Admission for atraumatic medical reasons (i.e. myocardial infarction, sepsis)

4. Consent cannot be obtained from the patient or their LAR within 12 hours of injury

5. Has already undergone fasciotomy of the injured leg prior to enrollment

6. Has spinal injuries that result in complete loss of function (complete spinal cord injuries)

7. Has bilateral upper and lower extremity injuries greater than simple soft tissue injuries

8. Is in police custody at presentation to the hospital

9. Is a woman who is pregnant

10. Has open injury on the injured leg that is large enough that at least two NIRS sensor cannot be safely placed. At a minimum two sensors must be placed on the injured leg(s).

Study Design


Intervention

Device:
Near Infrared Spectroscopy
Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.

Locations

Country Name City State
United States Brett A. Freedman, Col, MD Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Nonin Medical, Inc

Country where clinical trial is conducted

United States, 

References & Publications (2)

Reisman WM, Shuler MS, Roskosky M, Kinsey TL, Freedman BA. Use of Near-Infrared Spectroscopy to Detect Sustained Hyperaemia Following Lower Extremity Trauma. Mil Med. 2016 Feb;181(2):111-5. doi: 10.7205/MILMED-D-14-00689. — View Citation

Shuler MS, Roskosky M, Kinsey T, Glaser D, Reisman W, Ogburn C, Yeoman C, Wanderman NR, Freedman B. Continual near-infrared spectroscopy monitoring in the injured lower limb and acute compartment syndrome: an FDA-IDE trial. Bone Joint J. 2018 Jun 1;100-B( — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Acute Compartment Syndrome The subject develops and diagnosed with Acute Compartment Syndrome Zero to seventy two hours from enrollment.
See also
  Status Clinical Trial Phase
Completed NCT04113954 - Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers Phase 1
Terminated NCT03922139 - Botox for the Treatment of Chronic Exertional Compartment Syndrome Phase 1/Phase 2
Suspended NCT05006417 - Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome Phase 4
Enrolling by invitation NCT03359031 - Effects of Perioperative Patient Education Regarding Compartment Syndrome on Post-operative Opioid Consumption N/A
Completed NCT04442672 - Early Diagnosis of Compartment Syndrome by Multimodal Detection Technique N/A
Recruiting NCT05830721 - Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients N/A
Recruiting NCT06050499 - Chemical Analysis of Limb Microfluidics
Recruiting NCT04806555 - Diagnostic Value of Compression Ultrasound to Detect Acute Compartment Syndrome After Lower Limb Revascularisation N/A
Not yet recruiting NCT06079255 - Ischemia Detection During Development of Acute Compartment Syndrome
Recruiting NCT05466539 - Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A Phase 4